Severity
Moderate
FDA Drug recall · Reported May 8, 2019
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Customceutical Compounding recalled Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5,000IU/ML), 5 ML MULTIDOSE VIAL COMPO… - a moderate-severity action.
Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5,000IU/ML), 5 ML MULTIDOSE VIAL COMPO… was recalled by Customceutical Compounding in May 8, 2019. Reason: Lack of assurance of sterility for injectables and solutions intended to be sterile.. Check the official notice for the remedy. Verify recall #D-1259-2019 with the FDA Drug before acting.
The recall
Customceutical Compounding issued this moderate-severity FDA Drug recall-Lack of assurance of sterility for injectables and solutions intended to be sterile..
Sourced from official FDA Drug enforcement records. Verify recall #D-1259-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1259-2019) was formally reported on May 8, 2019, with the manufacturer initiating the action on April 8, 2019. It is classified under Moderate severity (Class II), with a current status of Terminated. Customceutical Compounding is listed as the recalling firm, operating out of Phoenix, AZ. Federal records list the affected scope as 2 vials.
The documented reason for this recall is: Lack of assurance of sterility for injectables and solutions intended to be sterile. Distribution data in the federal record shows the product reached: U.S.A. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 2,002 dietary supplements recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
2 vials
Related Recalls
6
0 from same agency
Test D (TESTOSTERONE CYPIONATE 200MG/ML VITAMIN D3 5,000IU/ML), 5 ML MULTIDOSE VIAL COMPOUNDED. Customceutical Compounding 4611 E. Shea Blvd. Bldg 3 180, Phoenix, AZ 85028 Ph. 480 516 0272
Lack of assurance of sterility for injectables and solutions intended to be sterile.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1259-2019 |
| Date reported | May 8, 2019 |
| Date initiated | April 8, 2019 |
| Recalling firm | Customceutical Compounding |
| Firm location | Phoenix, AZ |
| Affected scope | 2 vials |
| Distribution | U.S.A. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Pure Vitamins and Natural Supplements, LLC · 2026-04-15
Pure Vitamins and Natural Supplements, LLC · 2026-04-15
Herbal Creations USA · 2026-04-01
Winder Laboratories, LLC · 2026-03-25
Imu-Tek Animal Health, Incorporated · 2026-02-11
Compare this recall with Blue Bull Extreme Male Enhancement Supplement, total of 15 … →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 8, 2019. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.